{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:05:47Z","timestamp":1792800347495,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Many patients referred with a provisional diagnosis of cancer of unknown primary (pCUP) present with presumed metastatic disease to the liver. Due to the lack of definitive histological markers, intrahepatic cholangiocarcinoma (iCCA) may be overlooked. This study assessed the frequency of iCCA within a pCUP cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A single UK cancer-center study of sequential patients referred with pCUP from January 2017 to April 2020. Baseline diagnostic imaging was reviewed independently by a radiologist and oncologist; those with radiological features of iCCA (dominant liver lesion, capsular retraction) were identified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 228 patients referred with pCUP, 72 (32%) had malignancy involving the liver. 24\/72 patients had radiological features consistent with iCCA; they were predominantly female (75%) with an average age of 63 years and 63% had an ECOG PS\u2009\u2264\u20092. The median overall survival (OS) of the iCCA group and the remaining liver-involved CUP group were similar (OS 4.1 vs 4.4 months, <jats:italic>p<\/jats:italic>-value\u2009=\u20090.805). Patients, where a primary diagnosis was subsequently determined, had better OS (10.2 months, <jats:italic>p<\/jats:italic>-values: iCCA\u2009=\u20090.0279: cCUP\u2009=\u20090.0230).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this study, 34% of patients with liver-involved pCUP, fulfilled the radiological criteria for an iCCA diagnosis. Consideration of an iCCA diagnosis in patients with CUP could improve timely diagnosis, molecular characterisation and treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-022-01824-4","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T17:30:54Z","timestamp":1651167054000},"page":"531-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary"],"prefix":"10.1038","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2635-8206","authenticated-orcid":false,"given":"Alicia-Marie","family":"Conway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Vekeria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Backen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2272-3678","authenticated-orcid":false,"given":"Mair\u00e9ad G.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-0863","authenticated-orcid":false,"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-1082","authenticated-orcid":false,"given":"Natalie","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"1824_CR1","unstructured":"CRUK. UK Cancer statistics [Internet]. UK Cancer statistics. 2018. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/cancer-of-unknown-primary"},{"key":"1824_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMra1303917","volume":"371","author":"GR Varadhachary","year":"2014","unstructured":"Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med. 2014;371:757\u201365.","journal-title":"N Engl J Med"},{"key":"1824_CR3","unstructured":"NICE. National Institute for Health and Clinical Excellence Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104). NICE; 2010."},{"key":"1824_CR4","doi-asserted-by":"publisher","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","volume":"26","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v133\u20138.","journal-title":"Ann Oncol"},{"key":"1824_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.seminoncol.2008.10.006","volume":"36","author":"JD Hainsworth","year":"2009","unstructured":"Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol. 2009;36:44\u201351.","journal-title":"Semin Oncol"},{"key":"1824_CR6","doi-asserted-by":"publisher","first-page":"12440","DOI":"10.18632\/oncotarget.2574","volume":"5","author":"Z Gatalica","year":"2014","unstructured":"Gatalica Z, Millis SZ, Vranic S, Bender R, Basu GD, Voss A, et al. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget. 2014;5:12440\u20137.","journal-title":"Oncotarget."},{"key":"1824_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","volume":"1","author":"JS Ross","year":"2015","unstructured":"Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, et al. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol. 2015;1:40\u20139.","journal-title":"JAMA Oncol"},{"key":"1824_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejca.2018.02.021","volume":"94","author":"Z Gatalica","year":"2018","unstructured":"Gatalica Z, Xiu J, Swensen J, Vranic S. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. Eur J Cancer [Internet]. 2018;94:179\u201386. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.021.","journal-title":"Eur J Cancer [Internet]"},{"key":"1824_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41416-018-0332-2","volume":"120","author":"AM Conway","year":"2019","unstructured":"Conway AM, Mitchell C, Kilgour E, Brady G, Dive C, Cook N. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the \u201cU\u201d out of \u201cCUP.\u201d. Br J Cancer. 2019;120:141\u201353.","journal-title":"Br J Cancer"},{"key":"1824_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","volume":"31","author":"JD Hainsworth","year":"2013","unstructured":"Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: A prospective trial of the Sarah cannon research institute. J Clin Oncol. 2013;31:217\u201323.","journal-title":"J Clin Oncol"},{"key":"1824_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/annonc\/mdv543","volume":"27","author":"HH Yoon","year":"2016","unstructured":"Yoon HH, Foster NR, Meyers JP, Steen PD, Visscher DW, Pillai R, et al. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitacel and everolimus: NCCTG N0871 (alliance). Ann Oncol. 2016;27:339\u201344.","journal-title":"Ann Oncol"},{"key":"1824_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.18.00771","volume":"37","author":"H Hayashi","year":"2019","unstructured":"Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, et al. Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J Clin Oncol. 2019;37:570\u20139.","journal-title":"J Clin Oncol"},{"key":"1824_CR13","doi-asserted-by":"publisher","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","volume":"30","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Maillard A, Penel N, Baciarello G, Allouache D, Daugaard G, et al. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Ann Oncol. 2019;30:v851.","journal-title":"Ann Oncol"},{"key":"1824_CR14","doi-asserted-by":"publisher","first-page":"102882","DOI":"10.1016\/j.critrevonc.2020.102882","volume":"147","author":"E Rassy","year":"2020","unstructured":"Rassy E, Parent P, Lefort F, Boussios S, Baciarello G, Pavlidis N. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit? Crit Rev Oncol Hematol. 2020;147:102882.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1824_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clcc.2011.08.001","volume":"11","author":"JD Hainsworth","year":"2012","unstructured":"Hainsworth JD, Schnabel CA, Erlander MG, Haines DW, Greco FA. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer. 2012;11:112\u20138.","journal-title":"Clin Colorectal Cancer"},{"key":"1824_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10147-013-0583-0","volume":"19","author":"GR Varadhachary","year":"2014","unstructured":"Varadhachary GR, Karanth S, Qiao W, Carlson HR, Raber MN, Hainsworth JD, et al. Carcinoma of unknown primary with gastrointestinal profile: Immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol. 2014;19:479\u201384.","journal-title":"Int J Clin Oncol"},{"key":"1824_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty\u2010year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21:594\u20139.","journal-title":"Oncologist"},{"key":"1824_CR18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268\u201389.","journal-title":"J Hepatol"},{"key":"1824_CR19","doi-asserted-by":"crossref","unstructured":"Rothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019;25:738\u201343.","DOI":"10.1038\/s41591-019-0380-z"},{"key":"1824_CR20","doi-asserted-by":"publisher","first-page":"e769","DOI":"10.1002\/onco.13744","volume":"26","author":"C Pauli","year":"2021","unstructured":"Pauli C, Bochtler T, Mileshkin L, Baciarello G, Losa F, Ross JS, et al. A challenging task: identifying patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: the CUPISCO trial experience. Oncologist. 2021;26:e769\u201379.","journal-title":"Oncologist"},{"key":"1824_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023\u201331.","journal-title":"Nat Biotechnol"},{"key":"1824_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","volume":"17","author":"DR Borger","year":"2012","unstructured":"Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad\u2010based tumor genotyping. Oncologist. 2012;17:72\u20139.","journal-title":"Oncologist"},{"key":"1824_CR23","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/hep.26890","volume":"59","author":"Y Arai","year":"2014","unstructured":"Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427\u201334.","journal-title":"Hepatology."},{"key":"1824_CR24","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","volume":"45","author":"RP Graham","year":"2014","unstructured":"Graham RP, Barr Fritcher EG, Pestova E, Schulz J, Sitailo LA, Vasmatzis G, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45:1630\u20138.","journal-title":"Hum Pathol"},{"key":"1824_CR25","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.18632\/oncotarget.1943","volume":"5","author":"M Simbolo","year":"2014","unstructured":"Simbolo M, Fassan M, Ruzzenente A, Mafficini A, Wood LD, Corbo V, et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget. 2014;5:2839\u201352.","journal-title":"Oncotarget."},{"key":"1824_CR26","doi-asserted-by":"crossref","unstructured":"Churi CR, Shroff R, Wang Y, Rashid A, Kang HSC, Weatherly J, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS ONE. 2014;9:e115383.","DOI":"10.1371\/journal.pone.0115383"},{"key":"1824_CR27","doi-asserted-by":"crossref","unstructured":"Grassian AR, Pagliarini R, Chiang DY. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. Vol. 30, Curr Opin Gastroenterol. 2014;30:295\u2013302.","DOI":"10.1097\/MOG.0000000000000050"},{"key":"1824_CR28","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1245\/s10434-014-3828-x","volume":"21","author":"AX Zhu","year":"2014","unstructured":"Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014;21:3827\u201334.","journal-title":"Ann Surg Oncol"},{"key":"1824_CR29","doi-asserted-by":"publisher","first-page":"v872","DOI":"10.1093\/annonc\/mdz394.027","volume":"30","author":"GK Abou-Alfa","year":"2019","unstructured":"Abou-Alfa GK, Macarulla Mercade T, Javle M, Kelley RK, Lubner S, Adeva J, et al. ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Ann Oncol. 2019;30:v872\u20133.","journal-title":"Ann Oncol"},{"key":"1824_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.2019.37.4_suppl.187","volume":"37","author":"ZA Wainberg","year":"2019","unstructured":"Wainberg ZA, Lassen UN, Elez E, Italiano A, Curigliano G, De Braud FG, et al. Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E\u2013mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial. J Clin Oncol. 2019;37:187\u2013187.","journal-title":"J Clin Oncol."},{"key":"1824_CR31","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384.","journal-title":"Lancet Oncol"},{"key":"1824_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6:803\u201315.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1824_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1245\/s10434-014-4247-8","volume":"23","author":"CR Ferrone","year":"2016","unstructured":"Ferrone CR, Ting DT, Shahid M, Konstantinidis IT, Sabbatino F, Goyal L, et al. The ability to diagnose intrahepatic cholangiocarcinoma definitively using novel branched DNA-enhanced albumin RNA in situ hybridization technology. Ann Surg Oncol. 2016;23:290\u20136.","journal-title":"Ann Surg Oncol"},{"key":"1824_CR34","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","volume":"17","author":"S Moran","year":"2016","unstructured":"Moran S, Mart\u00ednez-Card\u00fas A, Sayols S, Musul\u00e9n E, Bala\u00f1\u00e1 C, Estival-Gonzalez A, et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 2016;17:1386\u201395.","journal-title":"Lancet Oncol"},{"key":"1824_CR35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41586-021-03512-4","volume":"594","author":"MY Lu","year":"2021","unstructured":"Lu MY, Chen TY, Williamson DFK, Zhao M, Shady M, Lipkova J, et al. AI-based pathology predicts origins for cancers of unknown primary. Nature. 2021;594:106\u201310.","journal-title":"Nature."},{"key":"1824_CR36","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"1824_CR37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, et al. Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36:276\u201382.","journal-title":"J Clin Oncol"},{"key":"1824_CR38","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2019.37.15_suppl.4117","volume":"37","author":"JO Park","year":"2019","unstructured":"Park JO, Feng Y-H, Chen Y-Y, Su W-C, Oh D-Y, Shen L, et al. Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. J Clin Oncol. 2019;37:4117\u20134117.","journal-title":"J Clin Oncol"},{"key":"1824_CR39","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/path.4251","volume":"231","author":"RW Tothill","year":"2013","unstructured":"Tothill RW, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P, et al. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol. 2013;231:413\u201323.","journal-title":"J Pathol"},{"key":"1824_CR40","doi-asserted-by":"publisher","first-page":"44322","DOI":"10.18632\/oncotarget.10035","volume":"7","author":"H L\u00f6ffler","year":"2016","unstructured":"L\u00f6ffler H, Pfarr N, Kriegsmann M, Endris V, Hielscher T, Lohneis P, et al. Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget. 2016;7:44322\u20139.","journal-title":"Oncotarget."},{"key":"1824_CR41","doi-asserted-by":"crossref","unstructured":"Subbiah IM, Tsimberidou A, Subbiah V, Janku F. Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience. 2017;4:47\u201356.","DOI":"10.18632\/oncoscience.352"},{"key":"1824_CR42","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-17-0628","volume":"77","author":"S Kato","year":"2017","unstructured":"Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, et al. Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary. Cancer Res. 2017;77:4238\u201346.","journal-title":"Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01824-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01824-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01824-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T23:22:18Z","timestamp":1659482538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01824-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8,1]]}},"alternative-id":["1824"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01824-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"8 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MGM received research grant support from Servier, Ipsen and NuCana. She has received travel and accommodation support from Bayer and Ipsen and speaker honoraria from Pfizer, Ipsen, NuCana and Mylan. She has served on advisory boards for Celgene, Ipsen, Sirtex, Baxalta and Incyte; all outside the scope of this work. AL received travel and educational support from Ipsen, Pfizer, Bayer, AAA, SirtEx, Novartis, Mylan and Delcath; speaker honoraria from Merck, Pfizer, Ipsen, Incyte, AAA, QED and Servier; advisory honoraria from EISAI, Nutricia Ipsen, QED, Roche and Servier; she is a member of the Knowledge Network and NETConnect Initiatives funded by Ipsen. JWV reports personal fees from Agios, personal fees from AstraZeneca, personal fees from Baxter, personal fees from Genoscience Pharma, personal fees from Hutchison Medipharma, personal fees from Imaging Equipment Ltd (AAA), personal fees from Incyte, personal fees from Ipsen, personal fees from Mundipharma EDO, personal fees from Mylan, grants, personal fees and non-financial support from NuCana, personal fees from QED, personal fees from Servier, personal fees from Sirtex, personal fees from Zymeworks, all outside the submitted work. NC: Advisory Board: Redx Pharmaceuticals, F. Hoffmann-La Roche Ltd, CUP Foundation. Funding to Research Institute: AstraZeneca, Orion, F. Hoffmann-La Roche Ltd, Taiho, GSK, Novartis, Starpharma, Bayer, Eisai, UCB, Redx Pharmaceuticals, Stemline Therapeutics, Boehringer Ingelheim, Merck, Tarveda Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. Data collection for this study was approved by a Quality Improvement and Clinical Audit Committee at a single institution (The Christie NHS Foundation Trust; reference number 2515; 17 April 2019). In the cases where residual diagnostic tissue remained from deceased individuals, and consent was not feasible ethical approval for subsequent tissue analysis was obtained from Yorkshire & The Humber\u2014Sheffield Research Ethics Committee (REC; reference approval ID 20\/YH\/0305).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent"}}]}}